We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

125 hedge funds and large institutions have $226M invested in Aldeyra Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 47 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

66% more call options, than puts

Call options by funds: $5.79M | Put options by funds: $3.49M

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

22% more capital invested

Capital invested by funds: $186M → $226M (+$40M)

6% more funds holding

Funds holding: 118125 (+7)

1% more ownership

Funds ownership: 62.45%63.45% (+1%)

43% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 47

Holders
125
Holders Change
+7
Holders Change %
+5.93%
% of All Funds
1.68%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
27
Reduced
47
Closed
14
Calls
$5.79M
Puts
$3.49M
Net Calls
+$2.3M
Net Calls Change
+$857K
Name Holding Trade Value Shares
Change
Change in
Stake
IC
51
IEQ Capital
California
$254K +$261K +44,145 New
AA
52
ALPS Advisors
Colorado
$252K -$25.7K -4,352 -9%
Jacobs Levy Equity Management
53
Jacobs Levy Equity Management
New Jersey
$218K +$225K +37,984 New
Verition Fund Management
54
Verition Fund Management
Connecticut
$216K +$222K +37,505 New
T. Rowe Price Associates
55
T. Rowe Price Associates
Maryland
$202K +$17.6K +2,978 +9%
First Manhattan
56
First Manhattan
New York
$200K
Citigroup
57
Citigroup
New York
$199K -$23.2K -3,932 -10%
Two Sigma Advisers
58
Two Sigma Advisers
New York
$190K -$545K -92,200 -74%
Franklin Resources
59
Franklin Resources
California
$186K +$191K +32,346 New
JPLA
60
Joseph P. Lucia & Associates
New York
$182K -$71 -12 -0%
Mirae Asset Global ETFs Holdings
61
Mirae Asset Global ETFs Holdings
Hong Kong
$172K +$7.38K +1,248 +4%
MIM
62
MetLife Investment Management
New Jersey
$162K -$3.49K -590 -2%
JP Morgan Chase
63
JP Morgan Chase
New York
$158K +$12.7K +2,150 +8%
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$156K +$123K +20,738 +326%
Russell Investments Group
65
Russell Investments Group
United Kingdom
$155K +$160K +27,042 New
CF
66
Corebridge Financial
Texas
$140K -$2.13K -361 -1%
IIM
67
INTECH Investment Management
Florida
$135K -$1.77K -300 -1%
XT
68
XTX Topco
Cayman Islands
$134K +$138K +23,332 New
FRM
69
Fox Run Management
Connecticut
$132K +$135K +22,912 New
PWA
70
Providence Wealth Advisors
Illinois
$130K
Commonwealth Equity Services
71
Commonwealth Equity Services
Massachusetts
$129K +$132K +22,395 New
HP
72
Hikari Power
Japan
$115K
Carson Wealth (CWM LLC)
73
Carson Wealth (CWM LLC)
Nebraska
$111K +$105K +17,722 +1,164%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$104K -$6.26K -1,059 -6%
SG Americas Securities
75
SG Americas Securities
New York
$102K -$26.9K -4,547 -20%

ALDX Hedge Fund Activity: Q1 2025 in Review

125 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2025, worth a combined $226M — up 22% from $186M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ALDX positions and 14 closed out — a net gain of 9 holders — while 27 added to existing stakes and 47 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $4.6M. The largest seller was ADAR1 Capital Management, cutting an estimated $2.58M.

  • 125 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2025, up from 118 in Q4 2024.
  • Funds reported $226M of Aldeyra Therapeutics stock for Q1 2025, up 22% quarter-over-quarter.
  • 23 funds opened new Aldeyra Therapeutics positions in Q1 2025 and 14 closed out, a net change of +9 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2025 was Kingdon Capital Management, an estimated $4.6M added.
  • The largest Aldeyra Therapeutics seller in Q1 2025 was ADAR1 Capital Management, an estimated $2.58M sold.

Based on aggregated 13F filings for Q1 2025.